Saturday, September 12, 2026

AI Terminator Fears Grow & Rates Breach 4.9% | The Weekly Wrap

Ten-year Treasury yields breach 4.9% as Steve Eisman discusses AI fears, OpenAI's price cut, Oracle's 30% revenue growth and Tesla's robotaxi setback.

TSLA $1.5TNVDA $5.4T

Steve Eisman Sep 11 2 clicks

Sep 11 LULU $11B

Lululemon: The 15-Minute Thesis

Hated Moats 2 clicks

Sep 11 LULU $11B

Why “Affordable Luxury” Doesn't Compound

MBI Deep Dives 2 clicks

From X

@MultiplesCap Sep 12

Multiples Capital on X

Not an AI expert by any stretch, but wonder if US labs actually coordinate to "pace the frontier," it could be a stealth negative for Nvidia’s top-line growth rate. Here’s why: Flattening the Frontier Race: If scaling massive base models is intentionally delayed for alignment, the panic to hoard the newest, most expensive contiguous GPU clusters cools down. Shift to Post-Training & RL: Progress shifts to squeezing intelligence out of existing models via synthetic data and self-play. This relies on inference-class rollout fleets rather than cutting-edge pre-training mega-clusters. The Verification Layer: Evaluating, sandboxing, and grading all that synthetic RL data requires massive CPU compute .... benefitting $INTC Less brute-force pre-training = extended hardware refresh cycles and a normalized upgrade curve for $NVDA. Markets much smarter on this than I, will wait into see how the stock prices react to this next week!

@Fierce__beast Sep 12

Fierce_beast on X

For $CASY, let's say it grows earnings roughly 6% on average for the next 20 years, then 3% terminally. Maybe its 9% for the next 5 years, but gradually moves toward something like maturity of 3%, average let's say is 6%. What multiple would you currently pay on that earnings stream? Personally, i would pay no more than 25x for this. Add other considerations to the business, maybe you think it will grow faster or longer, adjust your multiple as you prefer.

@negligible_cap Sep 12

Negligible Capital on X

“No one should be allowed to try and build better AI models than us” - Dario probably How come you never hear $META or $GOOG researchers crying wolf about the imminent dangers of AI? Or any open-sourced AI company? It’s seemingly always just Anthropic and OpenAI https://t.co/9UdFguBdPY

@negligible_cap Sep 12

Negligible Capital on X

“No one should be allowed to try and build better AI models than us” - Dario probably How come you never hear $META or $GOOG researchers crying wolf about the imminent dangers of AI? Or any open-sourced AI company? It’s always just Anthropic and OpenAI, which don’t have nearly the cashflow to support their operations like Meta or Alphabet or Alibaba. Let AI defend against AI, not regulation

@partners_road Sep 12

RiverRoadPartners on X

Stan gave the example of 2001. $CSCO had aggressively grown its backlog every yr through the Internet 1.0 buildout & the Street expected the same in 2001, but instead $CSCO’s backlog plunged. The build was over, & with that equipment demand evaporated. That will happen again. https://t.co/7yB6vDgcl8

@TidefallCapital Sep 12

Trevor Scott on X

my mistake $ADBE has a Nov year end. so it's 12x nov 2027, 14x nov 2026.

@finphysnerd Sep 12 1 click

Myles on X

I feel $GEO is a pretty decent short here. It's not cheap, and I might be politically biased, but I think it's hard to see Republicans getting many wins in the midterms, which the market will likely extrapolate to 2028.

@TidefallCapital Sep 11

Trevor Scott on X

I'll never understand going long $ADBE at 14x '27 when you can buy $CSU.TO at 15x '27. Maybe because it's Canadian listed.

The Five Deals That Made Apollo

Apollo Global Management’s five defining deals, from Executive Life to Intel, built a $1 trillion asset manager spanning insurance and…

APO $73B

Net Interest Sep 11 1 click

In Conversation: NVIDIA

NVIDIA sees inference, agentic workloads and robotics broadening AI compute demand beyond hyperscalers, while high-speed memory shortages…

NVDA $5.4T

Aurelion Research Sep 11 1 click

Apple: Why iPhone Duo Will Likely Dominate The Foldables Market

Apple’s iPhone Duo foldable pairs a TSMC 2 nm chip, IP68 protection and iOS 27 features, positioning it against Samsung’s Galaxy Z Fold 8.

AAPL $5T

Mark Hibben Sep 11 1 click

Broadcom (NASDAQ: AVGO) Stock Rating: Upgrade To Accumulate From Do Nothing - Accumulation Zone And Stop Inside

Broadcom was upgraded to Accumulate at about $363 after Q3 revenue reached $29.6 billion, with AI semiconductor revenue up 221% to $16.7…

AVGO $1.7T

Cestrian Capital Research. Sep 11

TSOH Weekly Roundup (09/11/2026)

TSOH weekly roundup covers Meta’s child-safety settlement, Markel’s leadership transition, Peloton’s gym strategy and an upcoming Alarm.com…

META $1.7TMKL $22B

TSOH Investment Research Sep 11 2 clicks

Independence Realty Buying Centerspace: Opportunity And Implications

Independence Realty Trust is buying Centerspace in stock to create an $8.1 billion apartment REIT, targeting 5% 2027 Core FFO per-share…

IRT $3.8B

Dane Bowler Sep 11

Applied Materials (NASDAQ: AMAT) Stock Rating: Upgrade To Accumulate After Q3 FY10/26 Earnings - Accumulation Zone And Stop Inside

Applied Materials reported Q3 revenue of $9.1 billion, up 25%, and $2.3 billion in free cash flow as AMAT fell roughly 40% from its June…

AMAT $375B

Cestrian Capital Research. Sep 11

Joby Aviation (NYSE: JOBY) Stock Rating: Accumulate - Initiating Coverage

Joby Aviation is initiated at Accumulate after booking $116m of trailing revenue, forming a Toyota manufacturing venture and agreeing to…

JOBY $6.4B

Cestrian Capital Research. Sep 11

Qualcomm Vs. Marvell: The Better AI Business Is The Worse Stock

Qualcomm offers more valuation cushion than Marvell despite Marvell’s stronger AI revenue, as its Amazon partnership supports data-center…

QCOM $203BMRVL $229B

Delta Analyst Sep 11

One of the Best Business Models in the World Just Went on Sale

AppLovin trades at 18 times EBITDA after a 57% drop, despite 84% EBITDA margins, rapid growth and a machine-learning advertising platform.

APP $104B

The Value Road Sep 10 5 clicks

TDC · short

Teradata CORP

Teradata is a short as its on-premises analytics business declines while enterprises shift workloads to cloud-native platforms.

TDC $2.7B

Value Investors Club May 16

Industrial and Commercial Bank of China

ICBC’s chairman describes embedding Chinese Communist Party leadership, anti-corruption campaigns and Xi Jinping Thought into governance at…

IDCBF $410B

John Hempton's Newsletter Nov 16

An Announcement, A Visit, A Stock Pitch

Cementos Argos trades below the value of its 54.7 million Summit Materials shares, with asset sales and strategic holdings providing…

CMTOY $4.5B

Exploring with Alluvial Capital Nov 11

One More for the Offshore Basket: An Orphaned Microcap Driller

Offshore drillers have fallen 25-30% despite floater dayrates above $500,000 and utilization in the high-80% to low-90% range.

TDW $4.3BVAL $5.8B

Raging Bull Investments Oct 24 1 click

Thinking aloud about Google remedies

Justice Department remedies could bar Google from using location data it cannot share, weakening targeted ads and traffic routing despite…

GOOGL $4.3T

John Hempton's Newsletter Oct 9 3 clicks

AngelAlign - Chinese clear aligners (6699 HK)

AngelAlign holds 3% of global clear aligners and sells about HK$10,000 below Invisalign in Hong Kong, alongside speculation that MBK could…

ALGN $11B

Healthy Stock Picks Sep 22

MNST Trading Below $53 Offers Nearly Risk-Free Return

Monster Beverage’s modified Dutch auction lets odd-lot holders buy 99 MNST shares below $53 and tender them at $53 to $60.

MNST $86B

Rod’s Ruminations May 23

Some Thoughts on Roaring Kitty

Roaring Kitty’s GameStop resurgence revisits GME shareholder activism and the meme-stock trading episode, with references to Bed Bath &…

GME $12B

Rod’s Ruminations May 21

(C)riminally (V)alued (S)caled Healthcare Services

CVS Health fell 20% after cutting 2024 adjusted EPS guidance to $7, but its Aetna insurance and Caremark PBM businesses support a…

CVS $111B

Rod’s Ruminations May 1

Sarepta Risk and the FDA

Sarepta’s Exondys 51 approval despite a 12-patient trial frames FDA regulatory risk and a call to remove Commissioner Robert Califf.

SRPT $2.2B

John Hempton's Newsletter Oct 31 1 click

Saturday, September 12, 2026

Multiples Capital on X

Fierce_beast on X

Negligible Capital on X

Negligible Capital on X

RiverRoadPartners on X

Trevor Scott on X

Myles on X

Trevor Scott on X

Investor Letters

Publications we follow

Newsletters 91

YouTube 4

Blogs 12

Seeking Alpha 29 of 161

X accounts we follow

Investor letters we follow

Sectors